CoChat

Atypical cellular responses mediated by intracellular constitutive active TrkB (NTRK2) kinase domains and a solely intracellular NTRK2-fusion oncogene

Open access

Published version of a preprint

The DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index.

Abstract

Trk ( NTRK ) receptor and NTRK gene fusions are oncogenic drivers of a wide variety of tumors. Although Trk receptors are typically activated at the cell surface, signaling of constitutive active Trk and diverse intracellular NTRK fusion oncogenes is barely investigated. Here, we show that a high intracellular abundance is sufficient for neurotrophin-independent, constitutive activation of TrkB kinase domains. In HEK293 cells, constitutive active TrkB kinase and an intracellular NTRK2-fusion oncogene (SQSTM1-NTRK2) reduced actin filopodia dynamics, phosphorylated FAK, and altered the cell morphology. Atypical cellular responses could be mimicked with the intracellular kinase domain, which did not activate the Trk-associated MAPK/ERK pathway. In glioblastoma-like U87MG cells, expression of TrkB or SQSTM1-NTRK2 reduced cell motility and caused drastic changes in the transcriptome. Clinically approved Trk inhibitors or mutating Y 705 in the kinase domain, blocked the cellular effects and transcriptome changes. Atypical signaling was also seen for TrkA and TrkC. Moreover, hallmarks of atypical pTrk kinase were found in biopsies of Nestin-positive glioblastoma. Therefore, we suggest Western blot-like immunoassay screening of NTRK-related (brain) tumor biopsies to identify patients with atypical panTrk or phosphoTrk signals. Such patients could be candidates for treatment with NTRK inhibitors such as Larotrectinhib or Entrectinhib.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41417-024-00809-0

Cites

82 of 82 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Abundance-dependent activation of TrkB kinase and changes in actin morphology strongly depend on phosphorylation in the YxxxYY-motif. A Model depicting TrkB kinase signaling. Neurotrophin (BDNF/NT-4)) binding induces conformational changes and supports receptor dimerization. The kinase is released from cis-autoinhibition, ATP binds to the intracellular kinase domain and allows trans-autophosphorylation. Three tyrosine residues in the consensus motif YxxxYY, Y701, Y705, and Y706 are phosphorylated in the activation loop of the receptor. ATP-binding and phosphorylation of the YxxxYY motif occur upstream of autophosphorylation and downstream signaling. In the intracellular domain (ICD), phosphorylation of Y515 recruits Shc and activates Ras/ERK and Pi3K-Akt pathways. Y816 forms an adapter site for PLCγ. S478 signals to the TIAM-Rac1 pathway. B TrkB phosphorylation in the absence of BDNF is unaffected by serum depletion. Western blotting of whole-cell lysates generated from HEK293 cells expressing TrkB. Control cultures were maintained in serum before total lysates were produced. The cell cultures were treated as indicated. Serum depletion was performed for 3 h. To inhibit TrkB kinase activity, the cultures were preincubated with 150 nM K252a, a Trk kinase inhibitor, for 30 min. DMSO was used as the solvent control. When indicated, cells were also treated with 20 ng/ml BDNF for 15 min and compared with BDNF-stimulated cells under K252a treatment. C Quantification of Western blots for pTrkB-kin normalized to the total Trk-kinase levels by densitometry. The relative integrated densities are also presented. K252a treatment for 30 min caused a reduction in TrkB phosphorylation levels under control, serum-depleted, and BDNF stimulation conditions. Bar graph: Mean ± SEM, overlaid with single data points; n = 3. D In the absence of neurotrophins, TrkB overexpression induces TrkB phosphorylation and changes cell morphology. Immunofluorescence of the TrkB receptor (green) and pTrk-PLCγ (red). F-actin was labeled with Acti-stain-670 phalloidin (blue). HEK293 cells were transfected with either TrkB- or TrkB-YFY kinase mutant. The cells were immunostained for 30 h. Yellow arrows indicate round pTrk-positive cells. Cyan arrows indicate filamentous pTrk-negative cells. Confocal images; scale bar:25 µm. E Filopodia phenotype of TrkB-expressing cells (high-resolution confocal stack image). F Round-shaped cells expressing kinase-active TrkB mutants. Immunostaining of HEK293 cells expressing either TrkB-wt or TrkB mutants (for details see Fig. S1). Cells expressing TrkB-wt or the constitutively active mutant TrkB-YDY were also treated with K252a. Typically, filamentous cells express kinase-dead ATP mutants of TrkB or YxxxYY mutants (YFY and YFF). Treatment with 150 nM K252a for 30 min reversed the round shape of the cells expressing TrkB-wt or TrkB-YDY. Confocal images; scale bar: 25 µm. G Quantification of the percentage of cells showing either a round shape or typical filopodia. Round cells were further subdivided into those that were either positive (+) or negative (−) for pTrk. Data were acquired from ten fields of view in three biological replicates (n = 3). Scale bar: 25 µm. H TrkB phosphorylation is correlated with TrkB expression. Linear positive correlation of the integrated density of anti-TrkB and anti-pTrkB-kin immunoreactivity in TrkB-expressing HEK293 cells. Immunolabels per cell were measured as the integrated density per cell from the maximum intensity projection images of confocal z-stacks. Single-cell data, n = 280 cells; data collected from 20 confocal image fields and 4 cell cultures (n = 4).
Fig. 1 Abundance-dependent activation of TrkB kinase and changes in actin morphology strongly depend on phosphorylation in the YxxxYY-motif. A Model depicting TrkB kinase signaling. Neurotrophin (BDNF/NT-4)) binding induces conformational changes and supports receptor dimerization. The kinase is released from cis-autoinhibition, ATP binds to the intracellular kinase domain and allows trans-autophosphorylation. Three tyrosine residues in the consensus motif YxxxYY, Y701, Y705, and Y706 are phosphorylated in the activation loop of the receptor. ATP-binding and phosphorylation of the YxxxYY motif occur upstream of autophosphorylation and downstream signaling. In the intracellular domain (ICD), phosphorylation of Y515 recruits Shc and activates Ras/ERK and Pi3K-Akt pathways. Y816 forms an adapter site for PLCγ. S478 signals to the TIAM-Rac1 pathway. B TrkB phosphorylation in the absence of BDNF is unaffected by serum depletion. Western blotting of whole-cell lysates generated from HEK293 cells expressing TrkB. Control cultures were maintained in serum before total lysates were produced. The cell cultures were treated as indicated. Serum depletion was performed for 3 h. To inhibit TrkB kinase activity, the cultures were preincubated with 150 nM K252a, a Trk kinase inhibitor, for 30 min. DMSO was used as the solvent control. When indicated, cells were also treated with 20 ng/ml BDNF for 15 min and compared with BDNF-stimulated cells under K252a treatment. C Quantification of Western blots for pTrkB-kin normalized to the total Trk-kinase levels by densitometry. The relative integrated densities are also presented. K252a treatment for 30 min caused a reduction in TrkB phosphorylation levels under control, serum-depleted, and BDNF stimulation conditions. Bar graph: Mean ± SEM, overlaid with single data points; n = 3. D In the absence of neurotrophins, TrkB overexpression induces TrkB phosphorylation and changes cell morphology. Immunofluorescence of the TrkB receptor (green) and pTrk-PLCγ (red). F-actin was labeled with Acti-stain-670 phalloidin (blue). HEK293 cells were transfected with either TrkB- or TrkB-YFY kinase mutant. The cells were immunostained for 30 h. Yellow arrows indicate round pTrk-positive cells. Cyan arrows indicate filamentous pTrk-negative cells. Confocal images; scale bar:25 µm. E Filopodia phenotype of TrkB-expressing cells (high-resolution confocal stack image). F Round-shaped cells expressing kinase-active TrkB mutants. Immunostaining of HEK293 cells expressing either TrkB-wt or TrkB mutants (for details see Fig. S1). Cells expressing TrkB-wt or the constitutively active mutant TrkB-YDY were also treated with K252a. Typically, filamentous cells express kinase-dead ATP mutants of TrkB or YxxxYY mutants (YFY and YFF). Treatment with 150 nM K252a for 30 min reversed the round shape of the cells expressing TrkB-wt or TrkB-YDY. Confocal images; scale bar: 25 µm. G Quantification of the percentage of cells showing either a round shape or typical filopodia. Round cells were further subdivided into those that were either positive (+) or negative (−) for pTrk. Data were acquired from ten fields of view in three biological replicates (n = 3). Scale bar: 25 µm. H TrkB phosphorylation is correlated with TrkB expression. Linear positive correlation of the integrated density of anti-TrkB and anti-pTrkB-kin immunoreactivity in TrkB-expressing HEK293 cells. Immunolabels per cell were measured as the integrated density per cell from the maximum intensity projection images of confocal z-stacks. Single-cell data, n = 280 cells; data collected from 20 confocal image fields and 4 cell cultures (n = 4).CC BY · PubMed Central
Fig. 2 Mutating of the YxxxYY-motif in TrkB restores actin filopodia dynamics. A, B Overexpression of TrkB kinase induces round-shaped cell morphology and loss of actin filopodia dynamics. HEK293 cells co-expressing GFP-actin and TrkB-wt (in A) or TrkB-YFF mutants (in B). Time-lapse images (in seconds) are shown. Living cells were imaged using a confocal laser-scanning microscope. GFP-labeled-actin was excited with a 488 nm laser, and fluorescence was detected using a spectral detector (510–570 nm). A Arrows point to a roundish cell that forms typical blebs. B The arrow indicates typical dynamic filopodia labeled by GFP-actin. Videos can be found in the supplement. Scale bar: 25 µm.
Fig. 2 Mutating of the YxxxYY-motif in TrkB restores actin filopodia dynamics. A, B Overexpression of TrkB kinase induces round-shaped cell morphology and loss of actin filopodia dynamics. HEK293 cells co-expressing GFP-actin and TrkB-wt (in A) or TrkB-YFF mutants (in B). Time-lapse images (in seconds) are shown. Living cells were imaged using a confocal laser-scanning microscope. GFP-labeled-actin was excited with a 488 nm laser, and fluorescence was detected using a spectral detector (510–570 nm). A Arrows point to a roundish cell that forms typical blebs. B The arrow indicates typical dynamic filopodia labeled by GFP-actin. Videos can be found in the supplement. Scale bar: 25 µm.CC BY · PubMed Central
Fig. 3 In HEK293 cells, constitutive active TrkB is upstream of focal adhesion kinase (FAK) phosphorylation. A Self-active TrkB-wt induces the phosphorylation of Focal Adhesion Kinase (FAK). Western blotting of whole-cell lysates generated from HEK293 cells expressing the indicated TrkB mutants. 150 nM K252a for 30 min was used to inhibit the Trk kinase activity. DMSO was used as the solvent control. Antibodies against total FAK, Cofilin and γ-Adaptin were used as loading controls. B Densitometric analysis of Western blots for pTrkB-kin normalized to the total TrkB levels in TrkB mutants. Means ± SEM, overlaid with single data points; n = 3. Note the high variability between biological replicates and failure of TrkB-kin activation in single samples. C pFAK signals were normalized to total FAK levels. The relative integrated densities are also presented. Means ± SEM, overlaid with single data points; n = 3. D Anti-pTrk signals in TrkB with mutations in the TrkB kinase domain or the ATP-binding site. E Anti-pTrk signals in TrkB with mutations in the Shc, PLCγ, or S478-adapter sites. F Self-active TrkB induces FAK phosphorylation This can be blocked by the Trk kinase inhibitor, K252a. Western blot of whole-cell lysates generated from HEK293 cells expressing TrkB-wt. G Quantification of Western blots for pTrkB-kin normalized to the total TrkB levels by densitometry. The relative integrated densities are also presented. K252a treatment reduces TrkB phosphorylation levels. Bar graph: mean ± SEM, overlaid with single data points; n = 7; 2-sample-t-test was performed: t(12) = 4.295, p = 0.00104. H Quantification of Western blots for pFAK normalized to the total FAK levels by densitometry. The relative integrated densities are also presented. K252a treatment reduced FAK phosphorylation levels. Bar graph: mean ± SEM, overlaid with single data points; n = 6; Mann–Whitney U test was performed: U = 32, p = 0.03064. I–K Modeling of TrkB. Superimposition (in I) of the TrkB MD model (blue) with the activated form of the insulin receptor (1gag, green). The YxxxYY motif is depicted in ball-and-stick mode. The YxxxYY motif of the autoinhibited insulin receptor is shown in gray and ball and stick modes. The backbone is omitted for clarity. The upper panel (in J) shows the superposition of the three MD models for TrkB. The wild-type is shown in blue. Phospho Y705 in orange and Y705F in purple. The YxxxYY motif is shown in the ball-and-stick mode, and the movement is indicated by an arrow (in K). UT.
Fig. 3 In HEK293 cells, constitutive active TrkB is upstream of focal adhesion kinase (FAK) phosphorylation. A Self-active TrkB-wt induces the phosphorylation of Focal Adhesion Kinase (FAK). Western blotting of whole-cell lysates generated from HEK293 cells expressing the indicated TrkB mutants. 150 nM K252a for 30 min was used to inhibit the Trk kinase activity. DMSO was used as the solvent control. Antibodies against total FAK, Cofilin and γ-Adaptin were used as loading controls. B Densitometric analysis of Western blots for pTrkB-kin normalized to the total TrkB levels in TrkB mutants. Means ± SEM, overlaid with single data points; n = 3. Note the high variability between biological replicates and failure of TrkB-kin activation in single samples. C pFAK signals were normalized to total FAK levels. The relative integrated densities are also presented. Means ± SEM, overlaid with single data points; n = 3. D Anti-pTrk signals in TrkB with mutations in the TrkB kinase domain or the ATP-binding site. E Anti-pTrk signals in TrkB with mutations in the Shc, PLCγ, or S478-adapter sites. F Self-active TrkB induces FAK phosphorylation This can be blocked by the Trk kinase inhibitor, K252a. Western blot of whole-cell lysates generated from HEK293 cells expressing TrkB-wt. G Quantification of Western blots for pTrkB-kin normalized to the total TrkB levels by densitometry. The relative integrated densities are also presented. K252a treatment reduces TrkB phosphorylation levels. Bar graph: mean ± SEM, overlaid with single data points; n = 7; 2-sample-t-test was performed: t(12) = 4.295, p = 0.00104. H Quantification of Western blots for pFAK normalized to the total FAK levels by densitometry. The relative integrated densities are also presented. K252a treatment reduced FAK phosphorylation levels. Bar graph: mean ± SEM, overlaid with single data points; n = 6; Mann–Whitney U test was performed: U = 32, p = 0.03064. I–K Modeling of TrkB. Superimposition (in I) of the TrkB MD model (blue) with the activated form of the insulin receptor (1gag, green). The YxxxYY motif is depicted in ball-and-stick mode. The YxxxYY motif of the autoinhibited insulin receptor is shown in gray and ball and stick modes. The backbone is omitted for clarity. The upper panel (in J) shows the superposition of the three MD models for TrkB. The wild-type is shown in blue. Phospho Y705 in orange and Y705F in purple. The YxxxYY motif is shown in the ball-and-stick mode, and the movement is indicated by an arrow (in K). UT.CC BY · PubMed Central
Fig. 4 The intracellular domain (ICD) of TrkB transduces signals to FAK, while a membrane-targeted ICD of TrkB is linked to MAPK phosphorylation. A Model depicting intracellular kinase-active domain constructs of TrkB. In Myr-ICD, an N-terminal myristoylation motif with a glycine-serine (GGSGG)-linker was used for plasma membrane targeting. The ICD (intracellular domain) construct lacks ligand-binding and transmembrane domains. The model includes the results of the experiment. Constitutively active TrkB-wt signals to MAPK and FAK, whereas Myr-ICD activates MAPK, but not FAK. ICD activates FAK but not MAPK. B TrkB-ICD and TrkB-Myr-ICD undergo self-activation but differ in their cellular localization patterns. Immunofluorescence of pTrk-kin (magenta), DAPI (blue) and Acti-stain-670 phalloidin (phall, green). HEK293 cells were immunostained 30 h after transfection. TrkB-ICD is preferentially observed at intracellular sites. The Myr-ICD construct showed typical plasma membrane targeting as expected. Note morphological changes in DAPI staining of ICD-expressing cells, indicating changes in chromatin compaction (cyan arrows) and pTrk-kin clusters (magenta arrows). Scale bar: 20 µm. C TrkB-ICD, but not TrkB-Myr-ICD, induced FAK phosphorylation. Western blotting of whole-cell lysates generated from HEK293 cells expressing TrkB-ICD, TrkB-Myr-ICD, TrkB-wt, or TrkB-YFF. K252a was used to inhibit the Trk kinase activity. TrkB-wt expression increased MAPK and FAK phosphorylation. ICD signaled to FAK, but not to MAPK. Myr-ICD induced MAPK phosphorylation but failed to activate FAK. D–F Quantification of Western blots for pTrkB-kin normalized to total TrkB levels (in D), pFAK to total FAK (in E), and pMAPK to total MAPK (in F). The relative integrated densities are also presented. Bar graph: Mean ± SEM, overlaid with single data points; n = 4. UT untransfected control.
Fig. 4 The intracellular domain (ICD) of TrkB transduces signals to FAK, while a membrane-targeted ICD of TrkB is linked to MAPK phosphorylation. A Model depicting intracellular kinase-active domain constructs of TrkB. In Myr-ICD, an N-terminal myristoylation motif with a glycine-serine (GGSGG)-linker was used for plasma membrane targeting. The ICD (intracellular domain) construct lacks ligand-binding and transmembrane domains. The model includes the results of the experiment. Constitutively active TrkB-wt signals to MAPK and FAK, whereas Myr-ICD activates MAPK, but not FAK. ICD activates FAK but not MAPK. B TrkB-ICD and TrkB-Myr-ICD undergo self-activation but differ in their cellular localization patterns. Immunofluorescence of pTrk-kin (magenta), DAPI (blue) and Acti-stain-670 phalloidin (phall, green). HEK293 cells were immunostained 30 h after transfection. TrkB-ICD is preferentially observed at intracellular sites. The Myr-ICD construct showed typical plasma membrane targeting as expected. Note morphological changes in DAPI staining of ICD-expressing cells, indicating changes in chromatin compaction (cyan arrows) and pTrk-kin clusters (magenta arrows). Scale bar: 20 µm. C TrkB-ICD, but not TrkB-Myr-ICD, induced FAK phosphorylation. Western blotting of whole-cell lysates generated from HEK293 cells expressing TrkB-ICD, TrkB-Myr-ICD, TrkB-wt, or TrkB-YFF. K252a was used to inhibit the Trk kinase activity. TrkB-wt expression increased MAPK and FAK phosphorylation. ICD signaled to FAK, but not to MAPK. Myr-ICD induced MAPK phosphorylation but failed to activate FAK. D–F Quantification of Western blots for pTrkB-kin normalized to total TrkB levels (in D), pFAK to total FAK (in E), and pMAPK to total MAPK (in F). The relative integrated densities are also presented. Bar graph: Mean ± SEM, overlaid with single data points; n = 4. UT untransfected control.CC BY · PubMed Central
Fig. 5 Treatment of TrkB-wt and SQSTM1-NTRK2 (a TrkB fusion product) with small molecule Trk inhibitors reduces or hinders downstream Trk activated pathways. A, C Immunostaining of HEK293 cells expressing TrkB-wt or SQSTM1-NTRK2. Immunofluorescence of TrkB (green), pTrk-kin (red) and Acti-stain-670 phalloidin (phall, blue). Cells were treated with small molecule Trk inhibitors like K252a, LOXO-101 and Entrectinib. TrkB self-activity is reduced upon inhibitor treatment. Confocal images; scale bar: 100 µm. B, D Western blotting of whole-cell lysates generated from HEK293 cells expressing TrkB-wt or SQSTM1-NTRK2. After transient transfection, the constructs were expressed for 30 h and then treated with small molecule Trk inhibitors like K252a, LOXO-101 and Entrectinib (concentrations are as depicted). Lysates were probed with the indicated antibodies via classical western blotting. Trk, FAK and MAPK activity was reduced upon inhibitor treatment. Downstream activity of FAK and MAPK was reduced upon inhibitor treatment. E Anti-SQSTM1/p62 detects the SQSTM1-NTRK2 fusion protein at the predicted relative molecular weight.
Fig. 5 Treatment of TrkB-wt and SQSTM1-NTRK2 (a TrkB fusion product) with small molecule Trk inhibitors reduces or hinders downstream Trk activated pathways. A, C Immunostaining of HEK293 cells expressing TrkB-wt or SQSTM1-NTRK2. Immunofluorescence of TrkB (green), pTrk-kin (red) and Acti-stain-670 phalloidin (phall, blue). Cells were treated with small molecule Trk inhibitors like K252a, LOXO-101 and Entrectinib. TrkB self-activity is reduced upon inhibitor treatment. Confocal images; scale bar: 100 µm. B, D Western blotting of whole-cell lysates generated from HEK293 cells expressing TrkB-wt or SQSTM1-NTRK2. After transient transfection, the constructs were expressed for 30 h and then treated with small molecule Trk inhibitors like K252a, LOXO-101 and Entrectinib (concentrations are as depicted). Lysates were probed with the indicated antibodies via classical western blotting. Trk, FAK and MAPK activity was reduced upon inhibitor treatment. Downstream activity of FAK and MAPK was reduced upon inhibitor treatment. E Anti-SQSTM1/p62 detects the SQSTM1-NTRK2 fusion protein at the predicted relative molecular weight.CC BY · PubMed Central
Fig. 6 Constitutive active TrkB and the SQSTM1-NTRK2 oncogene reduce migratory activity of U87MG cells. A Outline: inducible lentiviral expression vector. B Western blotting of whole-cell lysates generated from U87MG cells expressing the TrkB kinase construct. Cells transduced with the indicated lentiviral constructs were maintained as a polyclonal cell line, and puromycin was used to select transduced cells. In the absence of doxycycline, cells did not express the corresponding proteins. Doxycycline was added to induce Trk construct expression for 48 h. Constitutive activation of Trk was verified using pTrk-kin. γ−Adaptin was used as a loading control. C Representative phase-contrast microscopy images of the migration assay. U87MG cells stably expressing either TrkB-wt, TrkB-YFF, or the fusion protein SQSTM1-NTRK2 via the Tet-on system. The image in the upper left corner shows the cells in the culture after removing the silicone insert (t = 0). The other images represent the situation 24 h later. Note the morphological changes in TrkB-wt and SQSTM1-NTRK2 expressing cells versus TrkB-YFF. D Migratory activity of U87MG cells expressing the indicated Trk kinase constructs. The relative numbers of cells relative to the initial cell-free gap are shown. Cell counts were normalized to the mean number of TrkB-YFF-expressing cells. Migratory activity is shown relative to TrkB-YFF, which expresses the same structural protein domains as TrkB-wt but is mutated at Y705 and Y706 (see also S8); n = 4 biological replicates. E Immunostaining of U87MG cells expressing inducible TrkB-wt, TrkB-YFF, or the NTRK fusion construct SQSTM1-NTRK2. Immunofluorescence of the TrkB receptor domain (green), pTrk-kin (magenta), and Acti-stain-670 phalloidin (phall, cyan). Yellow arrows indicate constitutive pTrk close to F-actin. TrkB-YFF-expressing cells were labeled with anti-pTrk-PLCγ because the antibody-binding site of anti-pTrk-kin was mutated in this construct. SQSTM1-NTRK2 does not have a receptor domain, as indicated. Confocal z-stack images; scale bar: 50 µm.
Fig. 6 Constitutive active TrkB and the SQSTM1-NTRK2 oncogene reduce migratory activity of U87MG cells. A Outline: inducible lentiviral expression vector. B Western blotting of whole-cell lysates generated from U87MG cells expressing the TrkB kinase construct. Cells transduced with the indicated lentiviral constructs were maintained as a polyclonal cell line, and puromycin was used to select transduced cells. In the absence of doxycycline, cells did not express the corresponding proteins. Doxycycline was added to induce Trk construct expression for 48 h. Constitutive activation of Trk was verified using pTrk-kin. γ−Adaptin was used as a loading control. C Representative phase-contrast microscopy images of the migration assay. U87MG cells stably expressing either TrkB-wt, TrkB-YFF, or the fusion protein SQSTM1-NTRK2 via the Tet-on system. The image in the upper left corner shows the cells in the culture after removing the silicone insert (t = 0). The other images represent the situation 24 h later. Note the morphological changes in TrkB-wt and SQSTM1-NTRK2 expressing cells versus TrkB-YFF. D Migratory activity of U87MG cells expressing the indicated Trk kinase constructs. The relative numbers of cells relative to the initial cell-free gap are shown. Cell counts were normalized to the mean number of TrkB-YFF-expressing cells. Migratory activity is shown relative to TrkB-YFF, which expresses the same structural protein domains as TrkB-wt but is mutated at Y705 and Y706 (see also S8); n = 4 biological replicates. E Immunostaining of U87MG cells expressing inducible TrkB-wt, TrkB-YFF, or the NTRK fusion construct SQSTM1-NTRK2. Immunofluorescence of the TrkB receptor domain (green), pTrk-kin (magenta), and Acti-stain-670 phalloidin (phall, cyan). Yellow arrows indicate constitutive pTrk close to F-actin. TrkB-YFF-expressing cells were labeled with anti-pTrk-PLCγ because the antibody-binding site of anti-pTrk-kin was mutated in this construct. SQSTM1-NTRK2 does not have a receptor domain, as indicated. Confocal z-stack images; scale bar: 50 µm.CC BY · PubMed Central
Fig. 7 Constitutive kinase signaling of TrkB and SQSTM1-NTRK2 activates a specific transcriptome. A–F RNA-seq analysis of U87MG cells stably expressing either TrkB-wt, TrkB-YFF, or the fusion protein SQSTM1-NTRK2 via the Tet-on system: Volcano plots showing genes that were upregulated (right half) or downregulated (left half) depending on 48 h induction of TrkB (Dox) or upon further 24 h treatment with LOXO-101 (Loxo). Log2-fold-change values were plotted as P-adjusted values obtained from DESeq2 analysis of the transcriptome. Furthermore, the top 10–20 of these, up or down-regulated genes (and NTRK2) have been labeled (A–F). As a rule, up-regulated genes can be found on the right half of the volcano plots and down-regulated on the left. In (F), TrkB-wt (uninduced control) was compared to the U87MG cell line to eliminate possible underlying effects arising from the cell line or from the lentiviral infection itself. G, H Reactome analysis revealed a strong enrichment of genes involved in cellular immune defense responses, such as those required for interferon, chemokine, and interleukin signaling. Reactome with the top 20 biological pathways. Intracellular TkB kinase self-activation-induced immune responses (in G) overlap with those of the SQSTM1-NTRK2 fusion (in H). I Protein-protein interaction (metascape analysis) of upregulated genes found in TrkB-wt (Dox) as well as SQSTM1-NTRK2 (Dox). Data filtering: log2-fold upregulation, p-adjusted value < 0.05.
Fig. 7 Constitutive kinase signaling of TrkB and SQSTM1-NTRK2 activates a specific transcriptome. A–F RNA-seq analysis of U87MG cells stably expressing either TrkB-wt, TrkB-YFF, or the fusion protein SQSTM1-NTRK2 via the Tet-on system: Volcano plots showing genes that were upregulated (right half) or downregulated (left half) depending on 48 h induction of TrkB (Dox) or upon further 24 h treatment with LOXO-101 (Loxo). Log2-fold-change values were plotted as P-adjusted values obtained from DESeq2 analysis of the transcriptome. Furthermore, the top 10–20 of these, up or down-regulated genes (and NTRK2) have been labeled (A–F). As a rule, up-regulated genes can be found on the right half of the volcano plots and down-regulated on the left. In (F), TrkB-wt (uninduced control) was compared to the U87MG cell line to eliminate possible underlying effects arising from the cell line or from the lentiviral infection itself. G, H Reactome analysis revealed a strong enrichment of genes involved in cellular immune defense responses, such as those required for interferon, chemokine, and interleukin signaling. Reactome with the top 20 biological pathways. Intracellular TkB kinase self-activation-induced immune responses (in G) overlap with those of the SQSTM1-NTRK2 fusion (in H). I Protein-protein interaction (metascape analysis) of upregulated genes found in TrkB-wt (Dox) as well as SQSTM1-NTRK2 (Dox). Data filtering: log2-fold upregulation, p-adjusted value < 0.05.CC BY · PubMed Central
Fig. 8 Localization and expression of TrkB, panTrk and pTrk in grade IV glioblastoma. A Nestin/TrkB-positive cells in glioblastoma. Sections were labeled for anti-Nestin, to identify glioblastoma, and the TrkB receptor. Confocal laser scanning images. DAPI was used as the counterstain. Some Nestin+ cells show a high abundance of TrkB (cyan arrows). B Immunolabeling of representative glioblastoma cryosections. with anti-Nestin and anti-pTrk-kin. Single Nestin+ cells show a high abundance of pTrk-kin (upper panel, yellow arrows). Second and third panels: High-resolution confocal image stack showing pTrk in intracellular, immunoreactive clusters. Lower panel. Membrane bleb-like structures (yellow arrow) in single cells with strong intracellular pTrk-kin label. C RT-qPCR revealed abundant expression of TrkB kinase transcript in grade IV glioblastoma. Normalization of TrkB kinase expression levels in relation to RNA polymerase II. Single data points, mean values, and standard deviations are shown. The amplicon sizes were verified by agarose gel electrophoresis, as indicated. D Immature phospho-active Trk kinase in glioblastoma. Western blotting of whole-cell lysates generated from frozen post-mortem glioblastoma samples with the indicated antibodies. Lanes 1–6 show the lysates generated from different tissue pieces of the same glioblastoma sample. Note the high abundance of panTrk kinase and pTrk in one tissue sample (lane 2). Lane 7–9 shows representative TrkB-positive, panTrk kinase-negative, pTrk-kin-negative glioblastoma samples. This sample (pat. 1 (rec)) is a recurrent cancer sample from the same patient. γ-Adaptin was labeled as loading control. E TrkB and phospho-active Trk kinase in glioblastoma cells. Western blotting of whole-cell lysates from human brain or glioblastoma samples. Lanes 1–5 show control brain samples (frontal brain). PanTrk kinase immunoreactivity was observed at 130 kDa, indicating mature Trk (either TrkA, B or C). Lanes 6–9 show total lysates from different grade IV glioblastoma biopsies. Note the high abundance of panTrk kinase and pTrk-kin at approximately 90 kDa, indicating immature, phosphorylated Trk. For all the lanes, 40 µg of total protein was blotted.
Fig. 8 Localization and expression of TrkB, panTrk and pTrk in grade IV glioblastoma. A Nestin/TrkB-positive cells in glioblastoma. Sections were labeled for anti-Nestin, to identify glioblastoma, and the TrkB receptor. Confocal laser scanning images. DAPI was used as the counterstain. Some Nestin+ cells show a high abundance of TrkB (cyan arrows). B Immunolabeling of representative glioblastoma cryosections. with anti-Nestin and anti-pTrk-kin. Single Nestin+ cells show a high abundance of pTrk-kin (upper panel, yellow arrows). Second and third panels: High-resolution confocal image stack showing pTrk in intracellular, immunoreactive clusters. Lower panel. Membrane bleb-like structures (yellow arrow) in single cells with strong intracellular pTrk-kin label. C RT-qPCR revealed abundant expression of TrkB kinase transcript in grade IV glioblastoma. Normalization of TrkB kinase expression levels in relation to RNA polymerase II. Single data points, mean values, and standard deviations are shown. The amplicon sizes were verified by agarose gel electrophoresis, as indicated. D Immature phospho-active Trk kinase in glioblastoma. Western blotting of whole-cell lysates generated from frozen post-mortem glioblastoma samples with the indicated antibodies. Lanes 1–6 show the lysates generated from different tissue pieces of the same glioblastoma sample. Note the high abundance of panTrk kinase and pTrk in one tissue sample (lane 2). Lane 7–9 shows representative TrkB-positive, panTrk kinase-negative, pTrk-kin-negative glioblastoma samples. This sample (pat. 1 (rec)) is a recurrent cancer sample from the same patient. γ-Adaptin was labeled as loading control. E TrkB and phospho-active Trk kinase in glioblastoma cells. Western blotting of whole-cell lysates from human brain or glioblastoma samples. Lanes 1–5 show control brain samples (frontal brain). PanTrk kinase immunoreactivity was observed at 130 kDa, indicating mature Trk (either TrkA, B or C). Lanes 6–9 show total lysates from different grade IV glioblastoma biopsies. Note the high abundance of panTrk kinase and pTrk-kin at approximately 90 kDa, indicating immature, phosphorylated Trk. For all the lanes, 40 µg of total protein was blotted.CC BY · PubMed Central
Fig. 9 Expression of pTrk-kin in grade IV glioblastoma. Trk and phospho-active Trk kinase in glioblastoma. Western blotting of whole-cell lysates (40 µg per sample) generated from frozen glioblastoma samples with indicated antibodies. Total protein lysates from indicated tumor tissue pieces (see Table S2) were investigated. Note anti-pTrk-kin signals at 130 kDa in Nestin+ samples (in lanes for pat.10 and pat.15). In one recurrent sample (pat.14 (rec)), a strong anti-panTrk immunoreactivity appeared.
Fig. 9 Expression of pTrk-kin in grade IV glioblastoma. Trk and phospho-active Trk kinase in glioblastoma. Western blotting of whole-cell lysates (40 µg per sample) generated from frozen glioblastoma samples with indicated antibodies. Total protein lysates from indicated tumor tissue pieces (see Table S2) were investigated. Note anti-pTrk-kin signals at 130 kDa in Nestin+ samples (in lanes for pat.10 and pat.15). In one recurrent sample (pat.14 (rec)), a strong anti-panTrk immunoreactivity appeared.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 82 references

Cited by

See all 7

Metadata

Authors
Gupta, R., Dittmeier, M., Wohlleben, G., Nickl, V., Bischler, T., Luzak, V., Wegat, V., Doll, D., Sodmann, A., Bady, E., Langlhofer, G., Wachter, B., Havlicek, S., Gupta, J., Horn, E., Lüningschrör, P., Villmann, C., Polat, B., Wischhusen, J., Monoranu, C. M., Kuper, J., & Blum, R.
Affiliations
  • Universitätsklinikum Würzburg (DE)
  • University of Würzburg (DE)
  • Fraunhofer Institute for Interfacial Engineering and Biotechnology (DE)
  • University Medical Center Hamburg-Eppendorf (DE)
Corresponding author
Blum, Robert
Venue
Cancer Gene Therapy
Published
2024-07-22
Volume
31
Issue
9
Pages
1357-1379
ISSN
  • 0929-1903 (ISSN-L)
  • 1476-5500
OpenAlex
W4400896163
Cited by
7
References
82
Citations by year
2026: 2 · 2025: 5
FWCI
1.96
Type
journal article
Language
en
Open access
Licence
Locations
  • Cancer Gene Therapy (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, other-oa)
  • PubMed (publishedVersion)
  • Online Publication Service of Würzburg University (Würzburg University) (submittedVersion, cc-by)
  • PUBLISSO (German National Library of Medicine) (submittedVersion, cc-by)
  • Fraunhofer-Publica (Fraunhofer-Gesellschaft) (submittedVersion)
Funders
  • Deutsche Forschungsgemeinschaft (project-ID: 194101929 (BL567/3-2), project ID: 326998133; CRC TRR225 (B01))
  • Interdisziplinäres Zentrum für Klinische Forschung, Universitätsklinikum Würzburg (project Z-6, B-450)
  • Evangelisches Studienwerk Villigst
Topics
  • Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nerve injury and regeneration
Keywords
TrkB, NTRK2, constitutive kinase activation, focal adhesion kinase phosphorylation, cell morphology, cell motility, glioblastoma, TrkA, TrkC, TRK inhibitors, larotrectinib, entrectinib, transcriptome changes
MeSH terms
Cell Movement, Glioblastoma, Humans, Membrane Glycoproteins, Signal Transduction, Oncogene Proteins, Fusion, Receptor, trkB, Cell Line, Tumor, HEK293 Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Atypical cellular responses mediated by intracellular constitutive active TrkB (NTRK2) kinase domains and a solely intracellular NTRK2-fusion oncogene. https://app.cochat.ai/papers/10.1038/s41417-024-00809-0
The paper
Gupta, R., Dittmeier, M., Wohlleben, G., Nickl, V., Bischler, T., Luzak, V., Wegat, V., Doll, D., Sodmann, A., Bady, E., Langlhofer, G., Wachter, B., Havlicek, S., Gupta, J., Horn, E., Lüningschrör, P., Villmann, C., Polat, B., Wischhusen, J., . . . Blum, R. (2024). Atypical cellular responses mediated by intracellular constitutive active TrkB (NTRK2) kinase domains and a solely intracellular NTRK2-fusion oncogene. Cancer Gene Therapy. https://doi.org/10.1038/s41417-024-00809-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.